These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12571610)

  • 1. Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
    Grossman E
    J Hum Hypertens; 2003 Jan; 17(1):5-6. PubMed ID: 12571610
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone reduces urinary albumin excretion in type II diabetes.
    Bakris G; Viberti G; Weston WM; Heise M; Porter LE; Freed MI
    J Hum Hypertens; 2003 Jan; 17(1):7-12. PubMed ID: 12571611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rosiglitazone: a clinical development focused on cardio-vascular prevention].
    Valensi P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
    Sarafidis PA; Bakris GL
    Kidney Int; 2006 Oct; 70(7):1223-33. PubMed ID: 16883325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.
    Sarafidis PA; Stafylas PC; Georgianos PI; Saratzis AN; Lasaridis AN
    Am J Kidney Dis; 2010 May; 55(5):835-47. PubMed ID: 20110146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
    Zheng F; Guan Y
    Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone decreases albuminuria in type 2 diabetic patients.
    Miyazaki Y; Cersosimo E; Triplitt C; DeFronzo RA
    Kidney Int; 2007 Dec; 72(11):1367-73. PubMed ID: 17805239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.
    Pistrosch F; Herbrig K; Kindel B; Passauer J; Fischer S; Gross P
    Diabetes; 2005 Jul; 54(7):2206-11. PubMed ID: 15983223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medication of the month. Rosiglitazone (Avandia)].
    Scheen AJ
    Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
    Yamashita H; Nagai Y; Takamura T; Nohara E; Kobayashi K
    Metabolism; 2002 Apr; 51(4):403-8. PubMed ID: 11912544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and type 2 diabetes mellitus.
    Bragg T
    Lancet; 2001 May; 357(9266):1451. PubMed ID: 11360960
    [No Abstract]   [Full Text] [Related]  

  • 14. Selecting the right drug treatment for adults with type 2 diabetes.
    Montori VM
    BMJ; 2016 Mar; 352():i1663. PubMed ID: 27029501
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.
    Kim MK; Ko SH; Baek KH; Ahn YB; Yoon KH; Kang MI; Lee KW; Song KH
    Korean J Intern Med; 2009 Sep; 24(3):227-32. PubMed ID: 19721859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.
    Robinson S; Valabhji J; Schachter M
    BMJ; 2001 Feb; 322(7284):491. PubMed ID: 11222431
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Hitoglou-Makedou AD; Pagkalos EM; Yovos JG; Pliakos CI; Tourkantonis AA
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):227-34. PubMed ID: 15752951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones--a means to endpoint intervention.
    Jerkins TW
    Tenn Med; 2000 Nov; 93(11):403-5. PubMed ID: 11077884
    [No Abstract]   [Full Text] [Related]  

  • 20. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.